Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (251-260 of 520) with videos related to

Pageof 52
Sort By:
European Heart Journal|June 24, 2005
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registryKarolina E Szummer, Scott D Solomon, Eric J Velazquez, et al.
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Heart Journal|April 7, 2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)Colin Berry, Karen S Pieper, Harvey D White, et al.
European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
American Heart Journal|March 29, 2008
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialRachel E Anderson, Marc A Pfeffer, Jens Jakob Thune, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
JACC. Heart Failure|April 4, 2016
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection FractionJacob Joseph, Brian C Claggett, Inder S Anand, et al.
JACC. Heart Failure|October 10, 2024
Undiagnosed Diabetes in Heart Failure With Preserved Ejection FractionJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
Pageof 52

Showing results (251-260 of 520) with videos related to

Sort By:
Pageof 52
European Heart Journal|June 24, 2005
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registryKarolina E Szummer, Scott D Solomon, Eric J Velazquez, et al.
JAMA|October 13, 2005
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers, John J V McMurray, Karl Swedberg, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Heart Journal|April 7, 2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)Colin Berry, Karen S Pieper, Harvey D White, et al.
European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
American Heart Journal|March 29, 2008
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialRachel E Anderson, Marc A Pfeffer, Jens Jakob Thune, et al.
Journal of the American College of Cardiology|July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke DatabankG Michael Felker, Larry A Allen, Stuart J Pocock, et al.
JACC. Heart Failure|April 4, 2016
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection FractionJacob Joseph, Brian C Claggett, Inder S Anand, et al.
JACC. Heart Failure|October 10, 2024
Undiagnosed Diabetes in Heart Failure With Preserved Ejection FractionJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
Pageof 52